AGM vs NewGenIvf
AGMH and NIVF side by side. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How AGMH and NIVF compare
NewGenIvf grew revenue faster over the last twelve months (336% versus −4.6% for AGM).
NewGenIvf keeps more of each dollar of sales as profit, with a net margin of 41.7% compared with 1.8% at AGM.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | AGMH | NIVF |
|---|---|---|
| Size and price | ||
| Share price | $0.382 | $0.173 |
| Change, 1 year | −88.1% | −100.0% |
| Change, 5 years | −99.9% | – |
| Beta (5Y) | 3.03 | – |
| Employees | 11 | 87 |
| StockData Score | ||
| Total score | 7 | 7 |
| Valuation score | 0 | 0 |
| Growth score | 0 | 2 (better) |
| Performance score | 2 | 4 (better) |
| Health score | 5 (better) | 1 |
| Dividend score | 0 | 0 |
| Growth | ||
| Revenue growth (TTM) | −4.6% | 336% (better) |
| Revenue growth, 5Y average | 256% | – |
| Net income growth (TTM) | −82.0% | – |
| EPS growth (TTM) | −95.0% | – |
| Profitability | ||
| Gross margin | 10.3% (better) | 4.0% |
| Operating margin | −15.3% (better) | −45.2% |
| Net margin | 1.8% | 41.7% (better) |
| FCF margin | −13.3% (better) | −46.7% |
| Return on equity | 1.8% | 77.9% (better) |
| Return on invested capital | −7.9% (better) | −70.9% |
| Financial health | ||
| Debt / equity | 0.00 | – |
| Interest coverage | – | −17.4× |
| Current ratio | 13.27 (better) | 1.06 |
| Piotroski F-score | 4 | 5 (better) |
| Ownership | ||
| Held by institutions | 7.6% | – |
| Insider net buying, 12 months | – | $4.2M |
Go deeper
- AGMH stock overview
- AGMH income statement
- AGMH valuation and score
- NIVF stock overview
- NIVF income statement
- NIVF valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.